Legal entity
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: corporate-law. Ultragenyx Pharmaceutical Inc. is most often covered alongside Fermi Inc, which appears in 1 of these 2 stories. That works out to roughly 1.8 stories per week across an 8-day span. At 5, the average consequence score sits below the same-window beat average of 6.5. They are better corroborated than the beat average, carrying 3 original sources each against 2.9 for the same window. This profile follows 2 Legal stories mentioning Ultragenyx Pharmaceutical Inc. across the period from March 5, 2026 to March 12, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 352 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ultragenyx Pharmaceutical Inc.. Shared-story counts are live from our verified record — not editorial picks.
Lead Counsel Appointment
Expected timeframe for the court to designate the lead plaintiff and legal representation.
Lead Plaintiff Deadline
Final day for affected investors to petition the court to lead the class action.
Lead Plaintiff Deadline
Estimated deadline for investors to file motions to be appointed as lead plaintiff in the respective cases.
Lawsuit Announcements
Schall Law Firm files class action notices for Soleno Therapeutics and Ultragenyx Pharmaceutical.
Market Reaction
Investors and analysts begin assessing the potential litigation overhang on RARE, MREO, FRMI, and NAVN.
Investor Alerts Issued
Pomerantz Law Firm releases simultaneous reminders for class action lawsuits against four companies.
The Schall Law Firm has initiated securities fraud class actions against Soleno Therapeutics and Ultragenyx Pharmaceutical, alleging violations of federal securities laws. The firm is currently seeking lead plaintiffs to represent the class in these high-stakes biotech litigations following potential misrepresentations to the market.
Source: prnewswire.com · prnewswire.com
Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders.
Source: prnewswire.com · prnewswire.com
Ultragenyx Pharmaceutical Inc. is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
